Precigen stock jumps 77% after FDA approves PAPZIMEOS, the first therapy targeting adult recurrent respiratory papillomatosis ...

Fintel reports that on August 15, 2025, JP Morgan upgraded their outlook for Precigen (NasdaqGS:PGEN) from Underweight to ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults ...

"With the landmark FDA approval of PAPZIMEOS and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," ...

Papzimeos, the first-ever treatment approved for RRP is a moment for celebration and reflection FORT WORTH, Texas, August 15, 2025--(BUSINESS WIRE)--The Recurrent Respiratory Papillomatosis Foundation ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

Precigen (PGEN) stock jumps as the FDA approves the company's gene therapy Papzimeos for adults with recurrent respiratory ...